Visceral adiposity index and DHEAS are useful markers of diabetes risk in women with polycystic ovary syndrome

European Journal of Endocrinology

Volumn 172, Issue 1, 2015, Pages 79-88

  Amato, M C ^a   Magistro, A ^a   Gambino, G ^a   Vesco, R ^a   Giordano, C ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; PRASTERONE; BIOLOGICAL MARKER; GLUCOSE BLOOD LEVEL;

ADOLESCENT; ADULT; ANTHROPOMETRIC PARAMETERS; ARTICLE; BODY MASS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; GLUCOSE BLOOD LEVEL; HOMEOSTASIS; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; METABOLIC PARAMETERS; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DISPOSITIONAL INDEX; OVARY POLYCYSTIC DISEASE; RECEIVER OPERATING CHARACTERISTIC; RISK FACTOR; VISCERAL ADIPOSITY INDEX; WAIST CIRCUMFERENCE; BLOOD; DIABETES MELLITUS, TYPE 2; INTRAABDOMINAL FAT; METABOLISM; OBESITY; PHYSIOLOGY; POLYCYSTIC OVARY SYNDROME; YOUNG ADULT;

ADIPOSITY; ADOLESCENT; ADULT; BIOLOGICAL MARKERS; BLOOD GLUCOSE; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; INTRA-ABDOMINAL FAT; POLYCYSTIC OVARY SYNDROME; RISK FACTORS; YOUNG ADULT;

EID: 84920479724     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-14-0600     Document Type: Article

References (52)

1. Asuncion M, Calvo RM, San Millan JL, Sancho J, Avila S & Escobar-Morreale HF. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. Journal of Clinical Endocrinology and Metabolism 2000 85 2434-2438. (doi:10.1210/jcem.85.7.6682)
2. Diamanti-Kandarakis E., Kouli CR, Bergiele A.T., Filandra FA, Tsianateli TC, Spina GG, Zapanti ED & Bartzis MI. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. Journal of Clinical Endocrinology and Metabolism 1999 84 4006-4011. (doi:10.1210/jcem.84.11.6148)
3. Yildiz BO, Bozdag G, Yapici Z., Esinler I & Yarali H. Prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria. Human Reproduction 2012 27 3067-3073. (doi:10.1093/humrep/des232)
4. Galluzzo A, Amato MC & Giordano C. Insulin resistance and polycystic ovary syndrome. Nutrition, Metabolism, and Cardiovascular Diseases 2008 18 511-518. (doi:10.1016/j.numecd.2008.05.004)
5. Diamanti-Kandarakis E & Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocrine Reviews 2012 33 981-1030. (doi:10.1210/er.2011-1034)
6. Legro RS, Kunselman AR, Dodson WC & Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. Journal of Clinical Endocrinology and Metabolism 1999 84 165-169. (doi:10.1210/jcem.84.1.5393)
7. Ehrmann DA, Barnes RB, Rosenfield R.L., Cavaghan MK & Imperial J. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 1999 22 141-146. (doi:10. 2337/diacare.22.1.141)
8. Palmert MR, Gordon CM, Kartashov A.I., Legro RS, Emans SJ & Dunaif A. Screening for abnormal glucose tolerance in adolescents with poly-cystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 2002 87 1017-1023. (doi:10.1210/jcem.87.3.8305)
9. Alberti KG, Zimmet P & Shaw J. International Diabetes Federation: a consensus on type 2 diabetes prevention. Diabetic Medicine 2007 24 451-463. (doi:10.1111/j.1464-5491.2007.02157.x)
10. American Association of Clinical Endocrinologists Polycystic Ovary Syndrome Writing Committee. American Association of Clinical Endocrinologists position statement on metabolic and cardiovascular consequences of polycystic ovary syndrome. Endocrine Practice 2005 11 126-134. (doi:10.4158/Ep.11.2.125)
11. Salley KE, Wickham EP, Cheang K.I., Essah PA, Karjane NW & Nestler JE. Glucose intolerance in polycystic ovary syndrome - a position statement of the Androgen Excess Society. Journal of Clinical Endocrinology and Metabolism 2007 92 4546-4556. (doi:10.1210/jc.2007-1549)
12. Legro RS, Arslanian SA, Ehrmann D.A., Hoeger KM, Murad MH, Pasquali R & Welt CK. Diagnosis and treatment of polycystic ovary syndrome: an endocrine society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism 2013 98 4565-4592. (doi:10.1210/jc.2013-2350)
13. Hsu MI. Changes in the PCOS phenotype with age. Steroids 2013 78 761-766. (doi:10.1016/j.steroids.2013.04.005)
14. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Human Reproduction 2004 19 41-47. (doi:10.1093/humrep/deh098)
15. Ferriman D & Gallwey JD. Clinical assessment of body hair growth in women. Journal of Clinical Endocrinology and Metabolism 1961 21 1440-1447. (doi:10.1210/jcem-21-11-1440)
16. Azziz R, Carmina E, Dewailly D., Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W., Janssen OE, Legro RS, Norman RJ, Taylor AE et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertility and Sterility 2009 91 456-488. (doi:10.1016/j.fertnstert.2008.06.035)
17. Amato MC, Verghi M, Galluzzo A & Giordano C. The oligomenorrhoic phenotypes of polycystic ovary syndrome are characterized by a high visceral adiposity index: a likely condition of cardiometabolic risk. Human Reproduction 2011 26 1486-1494. (doi:10.1093/humrep/der088)
18. Christensen JT, Boldsen J & Westergaard JG. Ovarian volume in gynecologically healthy women using no contraception, or using IUD or oral contraception. Acta Obstetricia et Gynecologica Scandinavica 1997 76 784-789. (doi:10.3109/00016349709024348)
19. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) 2001 Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Journal of the American Medical Association 2001 285 2486-2497. (doi:10.1001/jama.285.19.2486)
20. American Diabetes Association. Standards of medical care in diabetes - 2014. Diabetes Care 2014 37 (Suppl 1) S14-S80. (doi:10.2337/dc14-S014)
21. Vermeulen A, Verdonck L & Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. Journal of Clinical Endocrinology and Metabolism 1999 84 3666-3672. (doi:10.1210/jcem.84.10.6079)
22. Matsuda M & De Fronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 2001 24 460-464. (doi:10.2337/diacare.24.3.460)
23. Utzschneider KM, Prigeon RL, Faulenbach M.V., Tong J., Carr DB, Boyko EJ, Leonetti DL, McNeely M.J., Fujimoto WY & Kahn SE. Oral disposition index predicts the development of future diabetes above and beyond fasting and 2-h glucose levels. Diabetes Care 2009 32 335-341. (doi:10.2337/dc08-1478)
24. Amato MC, Giordano C, Galia M., Criscimanna A, Vitabile S, Midiri M., Galluzzo A & AlkaMeSy Study Group. Visceral adiposity index: a reliable indicator of visceral fat function associated with cardiometabolic risk. Diabetes Care 2010 33 920-922. (doi:10.2337/dc09-1825)
25. Orentreich N, Brind HL, Rixer RL & Vogelman JH. Age changes and sex differences in serum dehydroepiandrosterone sulfate concentrations throughout adulthood. Journal of Clinical Endocrinology and Metabolism 1984 59 551-555. (doi:10.1210/jcem-59-3-551)
26. Fink RI, Kolterman OG, Griffin J & Olefsky JM. Mechanism of insulin resistance in aging. Journal of Clinical Investigation 1983 71 1523-1535. (doi:10.1172/JCI110908)
27. Rowe JW, Minaker KL, Pallotta HA & Flier JS. Characterization of the insulin resistance in aging. Journal of Clinical Investigation 1983 71 1581-1587. (doi:10.1172/JCI110914)
28. Paolisso G, Ammendola S, Rotandi M., Gambardella A, Rizzo MR, Mazziotti G, Tagliamonte M.R., Carella C & Varricchio M. Insulin resistance and advancing age: what role for dehydroepiandrosterone sulfate? Metabolism 1997 46 1281-1286. (doi:10.1016/S0026-0495(97)90231-6)
29. Legro RS, Gnatuk CL, Kunselman AR & Dunaif A. Changes in glucose tolerance over time in women with polycystic ovary syndrome: a controlled study. Journal of Clinical Endocrinology and Metabolism 2005 90 3236-3242. (doi:10.1210/jc.2004-1843)
30. Velling Magnussen L., Mumm H, Andersen M & Glintborg D. Hemoglobin A1c as a tool for the diagnosis of type 2 diabetes in 208 premenopausal women with polycystic ovary syndrome. Fertility and Sterility 2011 96 1275-1280. (doi:10.1016/j.fertnstert.2011.08.035)
31. Amato MC & Giordano C. Visceral adiposity index: an indicator of adipose tissue dysfunction. International Journal of Endocrinology 2014 730827. (doi:10.1155/2014/730827)
32. Oh JY, Sung YA & Lee HJ. The visceral adiposity index as a predictor of insulin resistance in young women with polycystic ovary syndrome. Obesity 2013 21 1690-1694. (doi:10.1002/oby.20096)
33. Androulakis K, Kandaraki E, Christakou C., Karachalios A, Marinakis E, Paterakis T & Diamanti-Kandarakis E. Visceral adiposity index (VAI) is related to the severity of anovulation and other clinical features in women with polycystic ovary syndrome. Clinical Endocrinology 2014 81 426-431. (doi:10.1111/cen.12447)
34. Wild RA, Carmina E, Diamanti-Kandarakis E, Dokras A., Escobar-Morreale HF, Futterweit W, Lobo R., Norman RJ, Talbott E & Dumesic DA. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. Journal of Clinical Endocrinology and Metabolism 2010 95 2038-2049. (doi:10.1210/jc.2009-2724)
35. Amato MC, Guarnotta V, Forti D., Donatelli M, Dolcimascolo S & Giordano C. Metabolically healthy polycystic ovary syndrome (MH-PCOS) and metabolically unhealthy polycystic ovary syndrome (MU-PCOS): a comparative analysis of four simple methods useful for metabolic assessment. Human Reproduction 2013 28 1919-1928. (doi:10.1093/humrep/det105)
36. Brennan K, Huang A & Azziz R. Dehydroepiandrosterone sulfate and insulin resistance in patients with polycystic ovary syndrome. Fertility and Sterility 2009 91 1848-1852. (doi:10.1016/j.fertnstert.2008.02.101)
37. Mottl R & Cerman J. A relationship between dehydroepiandrosterone sulfate and insulin resistance in obese men and women. Vnitrní Lékarství 2004 50 923-929.
38. Hoffman DI, Klove K & Lobo RA. The prevalence and significance of elevated dehydroepiandrosterone sulfate levels in anovulatory women. Fertility and Sterility 1984 42 76-81.
39. Steinberger E, Smith KD & Rodriguez-Rigau LJ. Testosterone, dehydroepiandrosterone, and dehydroepiandrosterone sulfate in hyperandrogenic women. Journal of Clinical Endocrinology and Metabolism 1984 59 471-477. (doi:10.1210/jcem-59-3-471)
40. Carmina E, Rosato F & Janni A. Increased DHEAs levels in PCO syndrome: evidence for the existence of two subgroups of patients. Journal of Endocrinological Investigation 1986 9 5-9. (doi:10.1007/BF03348052)
41. Hague WM, Honour JW, Adams J, Vecsei P & Jacobs HS. Steroid responses to ACTH in women with polycystic ovaries. Clinical Endocrinology 1989 30 355-365. (doi:10.1111/j.1365-2265.1989. tb00433.x)
42. Yildiz BO & Azziz R. The adrenal and polycystic ovary syndrome. Reviewsin Endocrine & Metabolic Disorders 2007 8331-342. (doi:10.1007/s11154-007-9054-0)
43. Chang WY, Knochenhauer ES, Bartolucci AA & Azziz R. Phenotypic spectrum of polycystic ovary syndrome: clinical and biochemical characterization of the three major clinical subgroups. Fertility and Sterility 2005 83 1717-1723. (doi:10.1016/j.fertnstert.2005.01.096)
44. Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W., Boots LR & Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. Journal of Clinical Endocrinology and Metabolism 1998 83 3078-3082. (doi:10.1210/jcem.83.9.5090)
45. Lerchbaum E, Schwetz V, Giuliani A., Pieber TR & Obermayer-Pietsch B. Opposing effects of dehydroepiandrosterone sulfate and free testosterone on metabolic phenotype in women with polycystic ovary syndrome. Fertility and Sterility 2012 98 1318-1325. (doi:10.1016/j.fertnstert.2012.07.1057)
46. Schunkert H, Hense HW, Andus T, Riegger GA & Straub RH. Relation between dehydroepiandrosterone sulfate and blood pressure levels in a populationbased sample. American Journal of Hypertension 1999 12 1140-1143. (doi:10.1016/S0895-7061(99)00128-4)
47. Hautanen A, Manttari M, Manninen V., Tenkanen L, Huttunen JK, Frick MH & Adlercreutz H. Adrenal androgens and testosterone as coronary risk factors in the Helsinki Heart Study. Atherosclerosis 1994 105 191-200. (doi:10.1016/0021-9150(94)90049-3)
48. Ohlsson C, Vandenput L & Tivesten A. DHEA and mortality: what is the nature of the association? Journal of Steroid Biochemistry and Molecular Biology 2014. In press. (doi:10.1016/j.jsbmb.2014.03.006)
49. Tchernof A & Labrie F. Dehydroepiandrosterone, obesity and cardiovascular disease risk: a review of human studies. European Journal of Endocrinology 2004 151 1-14. (doi:10.1530/eje.0.1510001)
50. Moghetti P, Castello R, Negri C., Tosi F, Spiazzi GG, Brun E, Balducci R., Toscano V & Muggeo M. Insulin infusion amplifies 17-α hydroxycor-ticosteroid intermediates response to adrenocorticotropin in hyperan-drogenic women: apparent relative impairment of 17,20-lyase activity. Journal of Clinical Endocrinology and Metabolism 1996 81 881-886. (doi:10.1210/jcem.81.3.8772544)
51. Arslanian SA, Lewy V, Danadian K & Saad R. Metformin therapy in obese adolescents with polycystic ovary syndrome and impaired glucose tolerance: amelioration of exaggerated adrenal response to adrenocorticotropin with reduction of insulinemia/insulin resistance. Journal of Clinical Endocrinology and Metabolism 2002 87 1555-1559. (doi:10.1210/jcem.87.4.8398)
52. Ortega-Gonzalez C., Luna S, Hernandez L., Crespo G, Aguayo P, Arteaga-Troncoso G & Parra A. Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 2005 90 1360-1365. (doi:10.1210/jc.2004-1965)